2021 American Transplant Congress
Use of a Novel Bead-based Assay to Measure the Impact of Imlifidase on ABO IgG Antibodies
*Purpose: The accurate assessment and measurement of ABO antibodies (ABO-Ab) is a critical component of ABO-incompatible (ABOi) transplantation. ABO-Ab comprise both IgG and IgM, which…2021 American Transplant Congress
Outcomes of Deceased Donor Transplants with Donor Specific Antibodies Before and After the New Kidney Allocation System
Columbia University, New York, NY
*Purpose: KAS forced centers to list unacceptable HLA antigens. Some centers excluded antigens at any level of anti-HLA Ab. Our center only excluded antibodies posing…2021 American Transplant Congress
Contribution of T-bet Expressing CD27+ CD21- Activated Memory B Cells Poised for Plasma Cell Differentiation to Antibody-mediated Rejection of Kidney Transplants
*Purpose: Alloimmunity triggered by donor-specific antibodies (DSAs) and ensuing development of antibody-mediated rejection (ABMR) are detrimental to organ transplants. Yet, the cellular states underlying B…2021 American Transplant Congress
The Relevance of Naturally Occurring Non-HLA Antibody to Antibody Mediated Rejection in Patients without Anti-HLA Antibodies After Kidney Transplantation
*Purpose: Very few papers describe the association between non-HLA antibodies and the incidence of antibody mediated rejection (AMR) in kidney recipients. We investigated the incidence…2021 American Transplant Congress
Novel Discovery of Super-antigen That Mobilize Regulatory Cd8 T Cells Inhibits Donor-specific Antibody and Protects Heart Allografts from Antibody-mediated Rejection
*Purpose: Antibody-mediated rejection (AMR) is a critical barrier to long-term allograft survival. We showed that Qa-1 (HLA-E in humans) restricted CD8+ T cells (CD8 Treg)…2021 American Transplant Congress
Safety and Tolerability of Tacrolimus Extended-Release (astagraf Xl) in Hla Sensitized Kidney Transplant Recipients: A Single Center Experience
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Pill burden is a limitation in kidney transplant. Tacrolimus extended-release (Astagraf XL) is a once daily formulation approved for kidney transplantation. Increased compliance could…2021 American Transplant Congress
DSA Causes Mild Molecular ABMR-like Changes in Many Biopsies Not Diagnosed as Rejection
1Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 2., ., AB, Canada
*Purpose: In the multicenter study INTERCOMEX, we developed a microarray-based system (MMDx) for diagnosing antibody-mediated and T cell-mediated rejection (ABMR, TCMR) in kidney transplant biopsies…2021 American Transplant Congress
Outcomes of Kidney Transplant Recipients with Antibody-mediated Allograft Rejection: A Retrospective Study
*Purpose: The optimal regimen for treating acute and chronic antibody-mediated rejection (AMR) in kidney transplant recipients has yet to be established. The purpose of the…2021 American Transplant Congress
The Trifecta Study: Calibrating Circulating Donor-Derived Cell-Free DNA at the Time of Indication Biopsies Against the Molecular Phenotype of the Biopsy Reveals a Prominent Association with NK Cell Genes
1Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, 2Natera Inc., San Carlos, CA
*Purpose: The international, multicenter, prospective Trifecta study was designed to calibrate dd-cfDNA% measurements in blood at the time of indication biopsy against the molecular characteristics…2021 American Transplant Congress
The Clinical Significance of Preformed Anti-HLA-DQ Donor-specific Antibodies on Allograft Outcomes in Kidney Transplantation
*Purpose: De-novo anti-HLA-DQ donor-specific antibody (DSA) has been identified as a risk factor for late graft dysfunction and graft loss in kidney transplantation (KT). The…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 40
- Next Page »